Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01882803
Title A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)
Acronym DYNAMO
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA | ITA | HUN | GBR | FRA | ESP | CZE | CAN | BGR | BEL


No variant requirements are available.